Here are three facts:
1. Mr. Blackford currently holds only 2,599 shares.
2. Out of 15 analysts covering NuVasive, 14 rate it “buy,” one “sell,” while six rate it “hold.”
3. Since March 2015, the stock had zero insider buys, and seven insider sales for $3.55 million in net activity.
More articles on devices:
SI-BONE, Aurora Spine, Xtant Medical & more — 25 key notes
NuVasive President & COO Patrick Miles sells 5k shares: 4 points
New study and licensing agreement for InVivo Therapeutics — 3 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
